CL2008003090A1 - Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer. - Google Patents

Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer.

Info

Publication number
CL2008003090A1
CL2008003090A1 CL2008003090A CL2008003090A CL2008003090A1 CL 2008003090 A1 CL2008003090 A1 CL 2008003090A1 CL 2008003090 A CL2008003090 A CL 2008003090A CL 2008003090 A CL2008003090 A CL 2008003090A CL 2008003090 A1 CL2008003090 A1 CL 2008003090A1
Authority
CL
Chile
Prior art keywords
ethanoate
indazol
methylphenyl
fluoro
urea
Prior art date
Application number
CL2008003090A
Other languages
English (en)
Inventor
B Borchardt Thomas
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003090(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of CL2008003090A1 publication Critical patent/CL2008003090A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n’-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparación; composición farmacéutica que la comprende; útiles en el tratamiento del cáncer.
CL2008003090A 2007-10-19 2008-10-17 Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer. CL2008003090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98123607P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CL2008003090A1 true CL2008003090A1 (es) 2009-11-27

Family

ID=40090209

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003090A CL2008003090A1 (es) 2007-10-19 2008-10-17 Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer.

Country Status (24)

Country Link
US (2) US7947843B2 (es)
EP (1) EP2195298B1 (es)
JP (1) JP5517940B2 (es)
KR (1) KR20100085116A (es)
CN (1) CN101827822B (es)
AR (1) AR068917A1 (es)
AU (1) AU2008312529A1 (es)
BR (1) BRPI0818065A8 (es)
CA (1) CA2699352C (es)
CL (1) CL2008003090A1 (es)
CO (1) CO6280481A2 (es)
CR (1) CR11388A (es)
DO (1) DOP2010000115A (es)
EC (1) ECSP10010188A (es)
ES (1) ES2460951T3 (es)
MX (1) MX2010004286A (es)
PA (1) PA8800201A1 (es)
PE (1) PE20091385A1 (es)
RU (1) RU2010119928A (es)
SG (1) SG185327A1 (es)
TW (1) TW200934485A (es)
UA (1) UA99746C2 (es)
UY (1) UY31407A1 (es)
WO (1) WO2009052226A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246333B1 (en) * 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) * 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
US20070104780A1 (en) 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
MX2009004861A (es) * 2006-11-09 2009-05-21 Abbott Gmbh & Co Kg Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
ES2460951T3 (es) 2014-05-16
WO2009052226A1 (en) 2009-04-23
KR20100085116A (ko) 2010-07-28
US7947843B2 (en) 2011-05-24
DOP2010000115A (es) 2010-10-15
UY31407A1 (es) 2009-05-29
CN101827822A (zh) 2010-09-08
TW200934485A (en) 2009-08-16
PA8800201A1 (es) 2009-05-15
JP2011500705A (ja) 2011-01-06
US8486988B2 (en) 2013-07-16
JP5517940B2 (ja) 2014-06-11
CR11388A (es) 2010-10-05
AU2008312529A1 (en) 2009-04-23
BRPI0818065A2 (pt) 2015-03-31
RU2010119928A (ru) 2011-11-27
AR068917A1 (es) 2009-12-16
CA2699352A1 (en) 2009-04-23
BRPI0818065A8 (pt) 2016-03-08
UA99746C2 (ru) 2012-09-25
CO6280481A2 (es) 2011-05-20
CA2699352C (en) 2016-06-21
CN101827822B (zh) 2013-06-19
PE20091385A1 (es) 2009-11-12
ECSP10010188A (es) 2010-06-29
EP2195298A1 (en) 2010-06-16
US20110196010A1 (en) 2011-08-11
EP2195298B1 (en) 2014-02-19
SG185327A1 (en) 2012-11-29
US20090118344A1 (en) 2009-05-07
MX2010004286A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ECSP10010361A (es) Derivados de piridazinona
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
EA201100030A1 (ru) Пиразольные соединения 436
TW200716628A (en) Novel compounds
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY30500A1 (es) Compuestos de azabencimidazolilo
CU23615B7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
ATE530524T1 (de) Substituierte sulfonamid-derivate
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.